Aurologistics Llc, (aurobindo Pharm

Aurologistics LLC, a subsidiary of Aurobindo Pharma USA Inc., is a pharmaceutical importer and distributor based in East Windsor, New Jersey. Established to manage the logistics and distribution of pharmaceutical products, Aurologistics plays a pivotal role in ensuring the efficient delivery of finished pharmaceutical formulations to the U.S. market. The company operates as a third-party logistics (3PL) provider, specializing in the importation and distribution of finished dosage forms, including tablets, capsules, syrups, and injections, sourced primarily from India. This strategic focus enables Aurologistics to support Aurobindo Pharma USA Inc. in its mission to provide a broad line of generic pharmaceuticals to the U.S. healthcare system.

Aurobindo Pharma USA Inc., the parent company of Aurologistics LLC, is a leading generic pharmaceutical company in the United States. The company is recognized for its vertically integrated supply chain, encompassing the manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. This integration allows Aurobindo to maintain stringent quality control and offer a diverse product portfolio across various therapeutic categories. The establishment of Aurologistics LLC underscores Aurobindo's commitment to enhancing its distribution capabilities, ensuring timely and efficient delivery of pharmaceutical products to meet the demands of the U.S. market.

Aurologistics LLC operates a state-of-the-art distribution center located at 203 Windsor Center Drive, East Windsor, NJ 08520. This facility spans 59 acres and is equipped with an Automatic Storage and Retrieval System (ASRS) featuring robotic arms and robots to handle inbound and outbound operations efficiently. The advanced logistics capabilities of this center enable Aurologistics to manage a high volume of shipments, ensuring the timely delivery of pharmaceutical products across the United States.

The distribution network of Aurologistics LLC is strategically designed to support the extensive product portfolio of Aurobindo Pharma USA Inc. By leveraging its advanced distribution infrastructure, Aurologistics ensures that a wide range of pharmaceutical products, including antibiotics, cardiovascular medications, and nutritional supplements, are readily available to meet the needs of healthcare providers and patients nationwide.

Aurologistics LLC serves as a critical component in the pharmaceutical supply chain within the United States, functioning as a third-party logistics (3PL) provider. Its primary role involves the importation and distribution of finished pharmaceutical formulations sourced from India, facilitating the efficient delivery of these products to the U.S. market. By managing the logistics and distribution processes, Aurologistics ensures that a diverse range of pharmaceutical products, including antibiotics, cardiovascular medications, and nutritional supplements, are accessible to healthcare providers and patients across the country.

The company's operations are closely integrated with Aurobindo Pharma USA Inc., reflecting a strategic partnership that enhances the overall efficiency and effectiveness of the pharmaceutical supply chain. This collaboration enables Aurologistics to leverage Aurobindo's manufacturing capabilities and product portfolio, ensuring a steady supply of high-quality pharmaceutical products to meet the demands of the U.S. healthcare system.

Aurologistics LLC's sourcing strategy is heavily concentrated on finished pharmaceutical formulations imported from India, particularly from its parent company, Aurobindo Pharma Ltd. This concentration reflects a strategic choice to leverage Aurobindo's vertically integrated supply chain, which encompasses the manufacturing of both active pharmaceutical ingredients (APIs) and finished dosage forms. By sourcing products from Aurobindo, Aurologistics benefits from consistent quality control, cost efficiencies, and a diverse product portfolio across various therapeutic categories.

The shipment data indicates a stable and reliable relationship between Aurologistics and its primary supplier, Aurobindo Pharma Ltd. The high volume of shipments and the consistent importation of a wide range of products suggest a well-established and dependable supply chain. This stability is crucial for maintaining uninterrupted access to essential pharmaceutical products in the U.S. market.

Aurologistics LLC's supply chain resilience is closely tied to the operations of its parent company, Aurobindo Pharma Ltd., in India. Aurobindo's vertically integrated supply chain, which includes the manufacturing of both APIs and finished dosage forms, provides a level of control and flexibility that enhances supply chain stability. This integration allows for efficient management of production and distribution processes, reducing the risk of supply disruptions.

While the primary sourcing from Aurobindo Pharma Ltd. offers significant advantages, it also means that Aurologistics' supply chain is closely linked to the operational stability and regulatory compliance of its Indian supplier. Ensuring that Aurobindo maintains high standards of quality control and adheres to international regulatory requirements is essential for sustaining the resilience of the supply chain.

The sourcing pattern of Aurologistics LLC, with a strong emphasis on products imported from India, particularly from Aurobindo Pharma Ltd., positions the company to leverage the efficiencies and quality control associated with its parent company's vertically integrated supply chain. This strategy enables Aurologistics to offer a diverse and high-quality product portfolio to the U.S. market, enhancing its competitive position.

For Indian exporters seeking to become alternative suppliers to Aurologistics, understanding the company's reliance on vertically integrated supply chains and its emphasis on quality control is crucial. Demonstrating compliance with international regulatory standards and the ability to meet the specific needs of the U.S. market will be key factors in establishing successful partnerships.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal requirements for drug products entering the U.S. market. This includes ensuring that imported drugs meet standards for quality, safety, and effectiveness.

Key legislation governing pharmaceutical imports includes the FD&C Act, which outlines the procedures for drug registration, labeling, and approval. The FDA's Regulatory Procedures Manual provides detailed guidance on import operations and actions, ensuring that imported drugs comply with U.S. regulations.

The marketing authorization pathway for Indian generics involves obtaining FDA approval, which requires demonstrating that the drug is safe and effective for its intended use. This process includes submitting an Abbreviated New Drug Application (ANDA) that provides evidence of bioequivalence to the reference listed drug. The FDA reviews these applications to ensure that imported generics meet the necessary standards before they can be marketed in the U.S.

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must ensure that their products comply with FDA regulations, including those related to drug registration and listing. While the FDA does not issue import licenses per se, importers must provide Affirmation of Compliance codes, such as the Drug Registration Number (REG), Drug Listing Number (DLS), and Drug Application Number (DA), to facilitate FDA review during the import process.

Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S), are generally accepted by the FDA. These certifications demonstrate that the manufacturing facilities adhere to international standards for quality and safety. Importers must ensure that their suppliers hold valid GMP certifications to meet FDA requirements.

Wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the United States. This authorization ensures that distributors comply with federal and state regulations governing the handling, storage, and distribution of drugs. Aurologistics LLC, as a distributor, must maintain the necessary licenses and adhere to these regulations to operate legally within the U.S. market.

Imported pharmaceutical products must undergo batch testing to ensure they meet FDA standards for quality, safety, and effectiveness. The FDA may collect samples of imported drugs for laboratory evaluation to verify compliance with applicable regulations. If a product fails to meet these standards, it may be refused entry into the United States.

Stability requirements for pharmaceutical products are established to ensure that drugs maintain their intended